AACE In the news

June 5, 2025 | The Guardian

Millions in West Do Not Know They Have Aggressive Fatty Liver Disease, Study Says

In a recent article by The Guardian, AACE President Scott D. Isaacs, MD, FACP, FACE, joins experts in responding to new research indicating that more than 15 million people in the US, UK, Germany, and France may have undiagnosed metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease linked to serious health risks. Experts emphasized the need for early screening in high-risk groups and continue to call for action to reduce stigma and improve liver health. The People-First Liver Charter, published in Nature Medicine and launched at the Global Think Tank on Steatotic Liver Disease, reinforces this message by advocating for a patient-centered approach to steatotic liver disease.

May 27, 2025 | Frontline Gastroenterology podcast

Role of Anti-Diabetic Medications in the Management of MASLD

In this episode of the Frontline Gastroenterology podcast, AACE President Scott D. Isaacs, MD, FACP, FACE, discusses the use of anti-diabetic medications such as pioglitazone or GLP-1 receptor agonists in the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Join Dr. Oliver Tavabie as he interviews Dr. Scott Isaacs and Dr. Paul Brennan to discuss key insights from their published paper, "Role of Anti-Diabetic Medications in the Management of MASLD."

May 27, 2025 | HELLO! Magazine

What is Ozempic smell? Here's all you need to know about the weight loss drug's latest side effect

As Ozempic and other GLP-1 weight-loss injections continue to gain popularity, users are reporting a curious side effect that has nothing to do with numbers on the scale: a dramatic shift in their sense of smell. In a recent HELLO! Magazine article, AACE President Scott D. Isaacs, MD, FACP, FACE, also draws attention to "Ozempic Feet," a lesser-known side effect in which rapid fat loss reduces foot padding, which may lead to pain and discomfort. Learn more by reading the full article.

May 25, 2025 | The Wall Street Journal

Should Everyone Be Taking Ozempic? Doctors Say More People Could Benefit

Anti-obesity drugs are showing promise for a growing list of conditions. In The Wall Street Journal, AACE President Scott D. Isaacs, MD, FACP, FACE, discusses the expanding role of GLP-1 medications in treating obesity, diabetes, and a fatty-liver condition called metabolic dysfunction-associated steatohepatitis (MASH), which affects an estimated 15 million Americans. The article also highlights broader research into the use of GLP-1s for heart and kidney disease, sleep apnea, and even Alzheimer’s.

May 15, 2025 | Medscape

Metal Ions: The Next Frontier in Diabetes Management?

Over 38 million adults in the United States have diabetes, according to the Centers for Disease Control and Prevention. Furthermore, the prevalence of diabetes has been steadily rising, increasing from 9.7% in 1999-2000 to 14.7% today. AACE President Scott D. Isaacs, MD, FACP, FACE, shares insights on how metal ion exposure may be contributing to rising diabetes rates in an article on Medscape.

May 6, 2025 | Health

What to Know About 'Ozempic Feet,' the Latest GLP-1 Side Effect Gaining Attention

Ozempic feet are characterized by sagging skin and reduced fat padding in the feet, which can occur with rapid weight loss. AACE President Scott D. Isaacs, MD, FACP, FACE, and AACE member Karl Nadolsky, DO, FACE, DABOM, explain that this side effect may occur with any significant and rapid weight loss. In an article by Health.com, they emphasize the importance of gradual weight loss, proper foot care, and ongoing medical oversight to manage related risks.

April 30, 2025 | Healio

New AACE guidance highlights treatments, genetic testing for MEN1-associated tumors

The 2025 Consensus Statement on the Management of Multiple Endocrine Neoplasia Type 1 (MEN1) has been published in Endocrine Practice. Dr. Jaydira Del Rivero, Chair of the MEN1 Consensus Statement Task Force, and Dr. Alexandra Gangi, Vice Chair, share their insights on the importance of early detection, multidisciplinary care, and individualized management for patients with MEN1 in an article featured on Healio.

April 28, 2025 | The Curbsiders Internal Medicine Podcast

Prediabetes and Diabetes Prevention with Dr. Scott Isaacs

Listen to episode #481 of The Curbsiders Internal Medicine Podcast, featuring AACE President, Scott D. Isaacs, MD, FACP, FACE, as he shares essential pearls on navigating screening tests for diabetes and prediabetes, identifying atypical cases of prediabetes, and individualizing management of prediabetes with lifestyle changes and medications.

April 25, 2025 | touchENDOCRINOLOGY

AACE 2025: Innovation, Education and Impact – A Letter from Dr. Scott Isaacs

AACE President, Scott D. Isaacs, MD, FACP, FACE, highlights key opportunities for health care professionals to expand their medical knowledge through AACE’s latest initiatives, including the 2025 Annual Meeting in Orlando, newly developed clinical guidance documents, expanded educational certificate programs, and more in an article on touchENDOCRINOLOGY.

March 20, 2025 | Healio

Biomarkers Identified by Machine Learning Could Assist in Diagnosing Liver Diseases

Machine learning may help identify biomarkers and develop predictive models that could assist in the diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic fibrosis, researchers reported. AACE President, Scott D. Isaacs, MD, FACP, FACE, shares his perspective on the study, highlighting its potential to improve MASLD diagnoses by providing noninvasive and cost-effective alternatives to liver biopsy. He emphasizes the need for further validation with liver biopsy data and integration into clinical practice could lead to earlier interventions, potentially reducing the progression of MASLD to more severe conditions like metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. Read the full article on Healio to learn more.

March 6, 2025 | Health

Zepbound Is Now Available in Additional Doses at Lower Costs

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug more accessible. AACE President Scott D. Isaacs, MD, FACP, FACE, and AACE member Karl Nadolsky, DO, FACE, DABOM, explain that these changes improve affordability for some patients without insurance coverage and expand access to a broader range of individuals. Read the full article on Health.com to learn more.

February 25, 2025 | Medscape

Screening and Management of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)

Dr. Carol H. Wysham interviews AACE President, Scott D. Isaacs, MD, FACP, FACE, on the Medscape InDiscussion: Type 2 Diabetes (Season 3) podcast to discuss the screening and management of metabolic dysfunction–associated steatotic liver disease (MASLD) in endocrine practice. Tune in to learn why MASLD is considered the hepatic complication of type 2 diabetes, the importance of FIB-4 screening, and how to optimize patient care with GLP-1s, SGLT2s, and emerging therapies. Plus, explore the critical role of lifestyle interventions in managing MASLD and reducing cardiovascular risk.

February 17, 2025 | Healio

AACE Guidance Examines Medication Options for Preventing ASCVD in Adults With Dyslipidemia

AACE published its first updated guideline on the pharmacologic management of adults with dyslipidemia since 2017, incorporating new recommendations for recently approved medications. Developed using the GRADE methodology, the guideline prioritizes patient-related factors, including social and economic considerations. AACE members Shailendra B. Patel, BM, ChB, DPhil, and Kathleen L. Wyne, MD, PhD, emphasize the need for more research on LDL cholesterol targets, diabetes, and metabolic liver disease. Read the full article on Healio for expert insights and key recommendations.

February 13, 2025 | Medscape

AACE Publishes Guideline on Drug Management of Dyslipidemia

AACE members Shailendra B. Patel, BM, ChB, DPhil, and Kathleen L. Wyne, MD, PhD, provide insights on the new AACE Clinical Practice Guideline for the Pharmacologic Management of Adults with Dyslipidemia. Based on the GRADE evidence-rating system, the guideline helps clinicians make informed treatment decisions by focusing on patient-important outcomes. They highlight that while newer cholesterol-lowering medications may offer benefits, their impact on major heart-related outcomes is limited, and certain risk assessment tests provide only small improvements in predicting cardiovascular disease. Read the full article on Medscape to explore these expert perspectives and key recommendations.

January 10, 2025 | Medscape

Are Patients On GLP-1s Getting the Right Nutrients?

As the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) continues to exponentially expand obesity treatment, concerns have arisen regarding their impact on nutrition in people who take them. AACE President, Scott D. Isaacs, MD, FACP, FACE, addresses these concerns in a Medscape article, providing key insights on optimizing patient outcomes through nutrition, education, and support.

December 12, 2024 | NPR News

Consultations for Obesity Drug Prescriptions Are Way Up Over 2023, Survey Finds

Appointments with health professionals for obesity drug consultations are way up, according to data from Zocdoc, a provider of scheduling services. AACE President Elect, Scott D. Isaacs, MD, FACP, FACE, explains that this trend reflects a growing recognition of obesity's health impacts, noting that as times change and awareness grows about the health benefits of weight loss, more people facing weight-related complications are seeking care, and the gender gap is starting to equalize. Despite this progress, high costs and limited insurance coverage still prevent many patients from accessing these medications. Learn more by listening to the full NPR News interview.

December 3, 2024 | The New York Times

Why Am I So Tired All the Time?

Feeling constantly tired despite getting enough sleep? Chronic exhaustion is common but often treatable. In this New York Times article, AACE President, Susan L. Samson, MD, PhD, FRCPC, FACE, highlights hypothyroidism as a potential cause of fatigue, explaining how it can be identified and treated effectively.

October 4, 2024 | Healio

Hepatic Steatosis Identified in More Than Half of Younger Adults Without History of MASLD

A recent Obesity study challenges assumptions about liver disease risk in younger populations, revealing high rates of hepatic steatosis and fibrosis among adults under 45. University of Florida researchers examined 1,420 adults without prior MASLD diagnosis, finding rates of these conditions in younger adults comparable to older individuals. This highlights the need for early screening, especially in those with risk factors like diabetes and obesity. AACE President-Elect, Scott D. Isaacs, MD, FACP, FACE, notes that MASLD is now the most common chronic liver disease in the U.S., affecting 25-30% of the population. He emphasizes the study's key finding that young adults with both obesity and type 2 diabetes show similar fibrosis rates to older adults, underscoring the critical importance of early intervention in this group.

September 25, 2024 | CNET

I Tracked My Blood Sugar for a Month. It Was an Emotional Roller Coaster

Biosensors that measure glucose are now available without a prescription. In a CNET article about a journalist's month-long experience with a continuous glucose monitor (CGM), AACE President Elect, Scott D. Isaacs, MD, FACP, FACE, offers key insights. He reassures that glucose spikes can be normal for people without diabetes after meals and shouldn't be overinterpreted. Dr. Isaacs highlights the benefits of CGMs as they provide more precise information than traditional A1C tests and can motivate people to take control of their health, while emphasizing the importance of understanding the device's limitations.

September 9, 2024 | touchENDOCRINOLOGY

Improving Global Endocrine Health: Initiatives from the American Association of Clinical Endocrinology (AACE)

AACE President, Susan L. Samson, MD, PhD, FRCPC, FACE, shares recent achievements and future initiatives in a new article on touchENDOCRINOLOGY. Key highlights include international growth, new certificate programs, and advocacy accomplishments.